These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

142 related articles for article (PubMed ID: 10927799)

  • 1. Changes in activated T cells in the blood correlate with disease activity in multiple sclerosis.
    Khoury SJ; Guttmann CR; Orav EJ; Kikinis R; Jolesz FA; Weiner HL
    Arch Neurol; 2000 Aug; 57(8):1183-9. PubMed ID: 10927799
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Serial magnetic resonance imaging in multiple sclerosis: correlation with attacks, disability, and disease stage.
    Weiner HL; Guttmann CR; Khoury SJ; Orav EJ; Hohol MJ; Kikinis R; Jolesz FA
    J Neuroimmunol; 2000 May; 104(2):164-73. PubMed ID: 10713356
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Expression of beta2 adrenoreceptors on peripheral blood mononuclear cells in patients with primary and secondary progressive multiple sclerosis: a longitudinal six month study.
    Zoukos Y; Thomaides TN; Kidd D; Cuzner ML; Thompson A
    J Neurol Neurosurg Psychiatry; 2003 Feb; 74(2):197-202. PubMed ID: 12531948
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Hypointense lesions on T1-weighted spin-echo magnetic resonance imaging: relation to clinical characteristics in subgroups of patients with multiple sclerosis.
    van Walderveen MA; Lycklama A Nijeholt GJ; Adèr HJ; Jongen PJ; Polman CH; Castelijns JA; Barkhof F
    Arch Neurol; 2001 Jan; 58(1):76-81. PubMed ID: 11176939
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Brain atrophy in relapsing-remitting multiple sclerosis and secondary progressive multiple sclerosis: longitudinal quantitative analysis.
    Ge Y; Grossman RI; Udupa JK; Wei L; Mannon LJ; Polansky M; Kolson DL
    Radiology; 2000 Mar; 214(3):665-70. PubMed ID: 10715027
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A longitudinal study of the T cell activation marker CD26 in chronic progressive multiple sclerosis.
    Constantinescu CS; Kamoun M; Dotti M; Farber RE; Galetta SL; Rostami A
    J Neurol Sci; 1995 Jun; 130(2):178-82. PubMed ID: 8586983
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Secondary progressive in contrast to relapsing-remitting multiple sclerosis patients show a normal CD4+CD25+ regulatory T-cell function and FOXP3 expression.
    Venken K; Hellings N; Hensen K; Rummens JL; Medaer R; D'hooghe MB; Dubois B; Raus J; Stinissen P
    J Neurosci Res; 2006 Jun; 83(8):1432-46. PubMed ID: 16583400
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Mitoxantrone: a review of its use in multiple sclerosis.
    Scott LJ; Figgitt DP
    CNS Drugs; 2004; 18(6):379-96. PubMed ID: 15089110
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Magnetic resonance spectroscopy of normal appearing white matter in early relapsing-remitting multiple sclerosis: correlations between disability and spectroscopy.
    Ruiz-Peña JL; Piñero P; Sellers G; Argente J; Casado A; Foronda J; Uclés A; Izquierdo G
    BMC Neurol; 2004 Jun; 4():8. PubMed ID: 15191618
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Analysis of effector CD4 (OX-40+) and CD8 (CD45RA+CD27-) T lymphocytes in active multiple sclerosis.
    Hintzen RQ; Pot K; Paty D; Oger J
    Acta Neurol Scand; 2000 Jan; 101(1):57-60. PubMed ID: 10660154
    [TBL] [Abstract][Full Text] [Related]  

  • 11. CD127 immunophenotyping suggests altered CD4+ T cell regulation in primary progressive multiple sclerosis.
    McKay FC; Swain LI; Schibeci SD; Rubio JP; Kilpatrick TJ; Heard RN; Stewart GJ; Booth DR
    J Autoimmun; 2008 Aug; 31(1):52-8. PubMed ID: 18406576
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cytokine producing CD8+ T cells are correlated to MRI features of tissue destruction in MS.
    Killestein J; Eikelenboom MJ; Izeboud T; Kalkers NF; Adèr HJ; Barkhof F; Van Lier RA; Uitdehaag BM; Polman CH
    J Neuroimmunol; 2003 Sep; 142(1-2):141-8. PubMed ID: 14512173
    [TBL] [Abstract][Full Text] [Related]  

  • 13. MRI as an outcome in multiple sclerosis clinical trials.
    Daumer M; Neuhaus A; Morrissey S; Hintzen R; Ebers GC
    Neurology; 2009 Feb; 72(8):705-11. PubMed ID: 19073945
    [TBL] [Abstract][Full Text] [Related]  

  • 14. ADC measurements in various patterns of multiple sclerosis lesions.
    Phuttharak W; Galassi W; Laopaiboon V; Laopaiboon M; Hesselink JR
    J Med Assoc Thai; 2006 Feb; 89(2):196-204. PubMed ID: 16579006
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Magnetization transfer magnetic resonance imaging and clinical changes in patients with relapsing-remitting multiple sclerosis.
    Oreja-Guevara C; Charil A; Caputo D; Cavarretta R; Sormani MP; Filippi M
    Arch Neurol; 2006 May; 63(5):736-40. PubMed ID: 16682543
    [TBL] [Abstract][Full Text] [Related]  

  • 16. MRI brain volume changes in relapsing-remitting multiple sclerosis patients treated with interferon beta-1a.
    Gasperini C; Paolillo A; Giugni E; Galgani S; Bagnato F; Mainero C; Onesti E; Bastianello S; Pozzilli C
    Mult Scler; 2002 Apr; 8(2):119-23. PubMed ID: 11990868
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Circulating CD8+CD56-perforin+ T cells are increased in multiple sclerosis patients.
    Giovanni F; Domenico P; Alessandro M; Raffaele I; Viviana N; Katia PA; Paola BA
    J Neuroimmunol; 2011 Dec; 240-241():137-41. PubMed ID: 22001684
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Human placenta-derived cells (PDA-001) for the treatment of adults with multiple sclerosis: a randomized, placebo-controlled, multiple-dose study.
    Lublin FD; Bowen JD; Huddlestone J; Kremenchutzky M; Carpenter A; Corboy JR; Freedman MS; Krupp L; Paulo C; Hariri RJ; Fischkoff SA
    Mult Scler Relat Disord; 2014 Nov; 3(6):696-704. PubMed ID: 25891548
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Voxelwise analysis of conventional magnetic resonance imaging to predict future disability in early relapsing-remitting multiple sclerosis.
    Wybrecht D; Reuter F; Zaaraoui W; Faivre A; Crespy L; Rico A; Malikova I; Confort-Gouny S; Soulier E; Cozzone PJ; Pelletier J; Ranjeva JP; Audoin B
    Mult Scler; 2012 Nov; 18(11):1585-91. PubMed ID: 22454097
    [TBL] [Abstract][Full Text] [Related]  

  • 20. One year activity on subtraction MRI predicts subsequent 4 year activity and progression in multiple sclerosis.
    Liguori M; Meier DS; Hildenbrand P; Healy BC; Chitnis T; Baruch NF; Khoury SJ; Weiner HL; Bakshi R; Barkhof F; Guttmann CR
    J Neurol Neurosurg Psychiatry; 2011 Oct; 82(10):1125-31. PubMed ID: 21429902
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.